RT Journal Article
SR Electronic
T1 Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1599
OP 1605
DO 10.21873/anticanres.15634
VO 42
IS 3
A1 YUKA MASUDA
A1 YOSHIKAZU KANANAZAWA
A1 KUNIHIKO MATSUNO
A1 DAISUKE KAKINUMA
A1 NOBUYUKI SAKURAZAWA
A1 FUMIHIKO ANDO
A1 NOBUTOSHI HAGIWARA
A1 TSUTOMU NOMURA
A1 SHUNJI KATO
A1 TOSHIRO YOSHIYUKI
A1 HIOSHI YOSHIDA
YR 2022
UL http://ar.iiarjournals.org/content/42/3/1599.abstract
AB Background/Aim: The impact of clinical response to taxanes plus ramucirumab (RAM) on overall survival (OS) has not been clarified for advanced gastric cancer (AGC), although this type of therapy is already in use as second-line chemotherapy (CTx). This study aimed to investigate the prognostic impact of the clinical response to taxanes plus ramucirumab (RAM) for AGC patients. Patients and Methods: This study included AGC patients treated with paclitaxel (PTX) or nab-paclitaxel (nab-PTX) and RAM. A retrospective analysis of response and survival rates in consecutive medical records of patients was performed. Results: Forty-two patients were enrolled. Median progression-free survival and OS were 5.4 months [95% confidence interval (CI)=4.440-6.361] and 11.8 months (95% CI=8.648-15.019), respectively. In Cox-hazard multivariate analysis, peritoneal metastasis [hazard ratio (HR)=2.830; 95% CI=1.320-6.067; p=0.008], and disease control rate (HR=0.310; 95% CI=0.129-0.741; p=0.008) were independent factors. Conclusion: The response to taxanes plus RAM CTx had an impact on the survival of patients with AGC.